Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"

NSCI (LON) 3,15 GBX

NetScientific announces shareholder name change

Jul 29, 2014

-

News, RNS Announcements

RNS Number : 6569N

NetScientific PLC

29 July 2014

NetScientific announces significant shareholder name change

NetScientific plc (AIM:NSCI, ‘NetScientific’ or ‘The Group’), the biomedical and healthcare technology investment group, has been informed by one of the Group’s significant shareholders, Quantadyne Limited, which owns 9.6% of the Company’s equity, that it has changed its name to White Mustard Investments.

For further information, please contact:

Liberum (Nomad & Broker)

Chris Bowman/Christopher Britton/Thomas Bective

Tel: 020 3100 2000

Bell Pottinger

Daniel de Belder/Kashara Taylor

Tel: 020 7861 3232

Company website: www.netscientific.net

ABOUT NETSCIENTIFIC

NetScientific is a healthcare and life sciences company with global reach that funds and develops technologies that offer transformative benefits to peoples’ lives and society through improved diagnosis, prognosis and treatment.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLLFFEDIIAFIS

NetScientific plc

6 Bevis Marks
1st floor, Bury Court
London
EC3A 7BA

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

copyright

NetScientific announces shareholder name change - NetScientific